marketcaparena
Search

    ACET

    Adicet Bio, Inc.

    Company overview

    Market capitalization
    $59.45M
    Employees
    102
    Latest publication
    2026-09-29
    About Adicet Bio, Inc.

    Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ3 20232023-09-30 · USD
    Total Revenue0USD0USD0USD0USD0USD6,506,000USD0USD0USD
    Cost Of Revenue1,342,000USD1,473,000USD1,600,000USD1,600,000USD1,680,000USD—1,592,000USD2,348,000USD
    Gross Profit-1,342,000USD-1,473,000USD-1,600,000USD-1,600,000USD-1,680,000USD3,253,000USD-1,592,000USD-2,348,000USD
    Research Development17,487,000USD25,036,000USD22,853,000USD28,424,000USD22,814,000USD23,273,000USD26,253,000USD26,167,000USD
    Selling General Administrative4,083,000USD6,850,000USD5,099,000USD3,968,000USD7,071,000USD7,470,000USD6,900,000USD6,633,000USD
    Unclassified Operating Expenses-1,342,000USD——————19,462,000USD
    Total Operating Expenses20,228,000USD31,886,000USD27,952,000USD32,392,000USD29,885,000USD30,743,000USD33,153,000USD52,262,000USD
    Operating Income-21,570,000USD-31,886,000USD-27,952,000USD-32,392,000USD-29,885,000USD-30,743,000USD-33,153,000USD-52,262,000USD
    Interest Income1,342,000USD1,524,000USD1,172,000USD1,398,000USD1,683,000USD2,067,000USD2,730,000USD2,520,000USD
    Interest Expense23,000USD24,000USD12,000USD0USD0USD1,000USD1,000USD1,000USD
    Net Interest Income1,319,000USD1,500,000USD1,160,000USD1,398,000USD1,683,000USD2,066,000USD2,729,000USD2,519,000USD
    Income Before Tax-20,244,000USD-30,516,000USD-26,856,000USD-31,217,000USD-28,214,000USD-28,727,000USD-30,478,000USD-49,885,000USD
    Tax Provision0USD0USD0USD0USD0USD0USD0USD0USD
    Net Income-20,244,000USD-30,516,000USD-26,856,000USD-31,217,000USD-28,214,000USD-28,727,000USD-30,478,000USD-49,885,000USD
    Net Income From Continuing Ops-20,244,000USD-30,516,000USD-26,856,000USD-31,217,000USD-28,214,000USD-28,727,000USD-30,478,000USD-49,885,000USD
    Ebit-20,221,000USD-30,492,000USD-26,844,000USD-31,217,000USD-28,214,000USD-28,726,000USD-30,477,000USD-49,884,000USD
    Ebitda-18,879,000USD-29,019,000USD-25,271,000USD-29,562,000USD-26,534,000USD-27,103,000USD-28,885,000USD-48,239,000USD
    Depreciation And Amortization1,342,000USD1,473,000USD1,573,000USD1,655,000USD1,680,000USD1,623,000USD1,592,000USD1,645,000USD
    Reconciled Depreciation1,342,000USD1,473,000USD1,573,000USD1,655,000USD1,680,000USD1,623,000USD1,592,000USD1,645,000USD
    Total Other Income Expense Net1,326,000USD1,370,000USD1,096,000USD1,175,000USD1,671,000USD2,016,000USD2,675,000USD2,377,000USD
    Income Tax Expense———————-141,000USD
    Net Income Applicable To Common Shares———————-49,885,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USDFY 20152015-12-31 · USDFY 20142014-12-31 · USD
    Total Revenue0USD0USD9,730,000USD17,903,000USD995,000USD8,181,000USD510,179,000USD499,690,000USD
    Cost Of Revenue6,381,000USD6,468,000USD——125,000USD80,000USD395,476,000USD401,419,000USD
    Gross Profit-6,381,000USD-6,468,000USD9,730,000USD17,903,000USD995,000USD8,101,000USD114,703,000USD98,271,000USD
    Research Development99,127,000USD99,323,000USD48,943,000USD34,334,000USD23,691,000USD14,717,000USD5,222,000USD2,834,000USD
    Selling General Administrative22,987,000USD28,292,000USD22,220,000USD22,760,000USD8,692,000USD8,428,000USD65,209,000USD61,021,000USD
    Unclassified Operating Expenses-6,381,000USD———————
    Total Operating Expenses115,733,000USD127,615,000USD71,163,000USD57,094,000USD32,383,000USD23,145,000USD70,431,000USD63,855,000USD
    Operating Income-122,114,000USD-127,615,000USD-61,433,000USD-39,191,000USD-31,388,000USD-14,964,000USD44,272,000USD34,416,000USD
    Interest Income5,777,000USD10,714,000USD91,000USD785,000USD————
    Interest Expense36,000USD4,000USD176,000USD134,000USD——2,100,000USD2,122,000USD
    Net Interest Income5,741,000USD10,710,000USD-85,000USD651,000USD————
    Income Before Tax-116,803,000USD-117,122,000USD-62,124,000USD-39,493,000USD-28,119,000USD-9,888,000USD44,674,000USD34,550,000USD
    Tax Provision0USD0USD-125,000USD-2,815,000USD————
    Net Income-116,803,000USD-117,122,000USD-61,999,000USD-36,678,000USD-28,138,000USD-9,299,000USD29,000,000USD22,328,000USD
    Net Income From Continuing Ops-116,803,000USD-117,122,000USD-61,999,000USD-36,678,000USD————
    Ebit-116,767,000USD-117,118,000USD-61,948,000USD-39,359,000USD-28,119,000USD-13,822,000USD46,774,000USD36,672,000USD
    Ebitda-110,386,000USD-110,650,000USD-60,410,000USD-37,408,000USD-26,881,000USD-13,742,000USD54,865,000USD43,616,000USD
    Depreciation And Amortization6,381,000USD6,468,000USD1,538,000USD1,951,000USD1,238,000USD80,000USD8,091,000USD6,944,000USD
    Reconciled Depreciation6,381,000USD6,468,000USD1,538,000USD1,226,000USD————
    Total Other Income Expense Net5,311,000USD10,493,000USD-691,000USD-302,000USD3,269,000USD5,076,000USD402,000USD134,000USD
    Income Tax Expense——-125,000USD-2,815,000USD19,000USD-589,000USD15,674,000USD12,222,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets148,166,000USD169,382,000USD192,355,000USD140,479,000USD162,972,000USD191,271,000USD220,219,000USD245,962,000USD
    Cash And Equivalents33,131,000USD———————
    Total Current Assets120,763,000USD140,071,000USD160,926,000USD106,494,000USD127,740,000USD153,563,000USD180,136,000USD206,316,000USD
    Other Current Assets2,573,000USD2,074,000USD2,054,000USD3,227,000USD2,777,000USD3,124,000USD3,833,000USD4,041,000USD
    Other Non Current Assets80,000USD———————
    Total Liabilities28,028,000USD———————
    Total Current Liabilities18,001,000USD18,298,000USD21,531,000USD18,941,000USD17,079,000USD16,447,000USD19,392,000USD19,394,000USD
    Other Non Current Liabilities0USD———————
    Total Stockholder Equity120,138,000USD140,065,000USD159,210,000USD109,142,000USD133,372,000USD161,446,000USD186,609,000USD211,531,000USD
    Total Equity Including Noncontrolling Interest120,138,000USD———————
    Property Plant Equipment Net23,566,000USD26,364,000USD28,481,000USD30,972,000USD32,104,000USD34,491,000USD36,752,000USD39,138,000USD
    Accounts Payable3,592,000USD2,929,000USD4,739,000USD4,287,000USD3,292,000USD4,403,000USD4,830,000USD2,500,000USD
    Short Term Debt2,655,000USD2,879,000USD3,186,000USD3,265,000USD2,953,000USD2,983,000USD3,132,000USD3,278,000USD
    Common Stock1,000USD1,000USD10,000USD8,000USD8,000USD8,000USD8,000USD8,000USD
    Retained Earnings-656,299,000USD-634,941,000USD-614,697,000USD-584,181,000USD-557,325,000USD-526,108,000USD-497,894,000USD-469,167,000USD
    Accumulated Other Comprehensive Income-105,000USD-37,000USD102,000USD56,000USD-41,000USD-9,000USD16,000USD121,000USD
    Total Liab—29,317,000USD33,145,000USD31,337,000USD29,600,000USD29,825,000USD33,610,000USD34,431,000USD
    Other Current Liab—12,490,000USD13,606,000USD11,389,000USD10,834,000USD9,061,000USD11,430,000USD13,616,000USD
    Capital Stock—1,000USD10,000USD8,000USD8,000USD8,000USD8,000USD8,000USD
    Cash—36,245,000USD38,918,000USD29,099,000USD34,720,000USD28,133,000USD56,495,000USD105,482,000USD
    Cash And Short Term Investments—137,592,000USD158,530,000USD103,098,000USD124,963,000USD150,439,000USD176,303,000USD202,065,000USD
    Net Debt—-22,347,000USD-24,180,000USD-13,563,000USD-19,362,000USD-11,888,000USD-39,261,000USD-87,283,000USD
    Short Long Term Debt Total—13,898,000USD14,738,000USD15,536,000USD15,358,000USD16,245,000USD17,234,000USD18,199,000USD
    Short Term Investments—101,347,000USD119,612,000USD73,999,000USD90,243,000USD122,306,000USD119,808,000USD96,583,000USD
    Net Receivables—405,000USD342,000USD169,000USD———210,000USD
    Property Plant Equipment Gross—55,094,000USD55,868,000USD56,887,000USD56,446,000USD57,487,000USD58,067,000USD58,831,000USD
    Common Stock Shares Outstanding—10,744,621shares6,891,336shares5,692,904shares5,692,844shares5,691,965shares5,491,652shares5,677,893shares
    Non Current Assets Total—29,311,000USD31,429,000USD33,985,000USD35,232,000USD37,708,000USD40,083,000USD39,646,000USD
    Non Current Liabilities Total—11,019,000USD11,614,000USD12,396,000USD12,521,000USD13,378,000USD14,218,000USD15,037,000USD
    Non Currrent Assets Other—78,000USD76,000USD110,000USD225,000USD3,217,000USD3,331,000USD508,000USD
    Net Working Capital—121,773,000USD139,395,000USD87,553,000USD110,661,000USD137,116,000USD160,744,000USD186,922,000USD
    Unclassified Non Current Assets—2,869,000USD2,872,000USD2,903,000USD2,903,000USD———
    Unclassified Non Current Liabilities—11,019,000USD11,552,000USD12,271,000USD12,405,000USD13,262,000USD14,102,000USD14,921,000USD
    Unclassified Equity—775,041,000USD773,785,000USD693,251,000USD690,722,000USD687,547,000USD684,471,000USD680,561,000USD
    Non Current Liabilities Other——62,000USD125,000USD116,000USD116,000USD116,000USD116,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets192,355,000USD220,219,000USD207,295,000USD330,690,000USD338,938,000USD153,835,000USD81,587,000USD109,939,000USD
    Other Current Assets2,054,000USD3,833,000USD2,561,000USD2,947,000USD4,680,000USD2,991,000USD851,000USD938,000USD
    Total Liab33,145,000USD33,610,000USD37,120,000USD38,352,000USD35,809,000USD44,008,000USD141,953,000USD5,735,000USD
    Total Stockholder Equity159,210,000USD186,609,000USD170,175,000USD292,338,000USD303,129,000USD109,827,000USD-60,366,000USD104,204,000USD
    Other Current Liab13,606,000USD11,430,000USD13,441,000USD12,811,000USD6,682,000USD5,732,000USD2,820,000USD5,178,000USD
    Common Stock10,000USD8,000USD4,000USD4,000USD4,000USD2,000USD4,000USD3,000USD
    Capital Stock10,000USD8,000USD4,000USD4,000USD4,000USD2,000USD——
    Retained Earnings-614,697,000USD-497,894,000USD-380,772,000USD-238,114,000USD-168,324,000USD-106,325,000USD-69,647,000USD-71,393,000USD
    Cash38,918,000USD56,495,000USD159,711,000USD257,656,000USD277,544,000USD84,330,000USD10,607,000USD7,042,000USD
    Cash And Short Term Investments158,530,000USD176,303,000USD159,711,000USD257,656,000USD277,544,000USD94,614,000USD62,400,000USD108,028,000USD
    Total Current Assets160,926,000USD180,136,000USD162,272,000USD261,038,000USD282,438,000USD100,336,000USD64,186,000USD109,534,000USD
    Total Current Liabilities21,531,000USD19,392,000USD19,287,000USD19,707,000USD16,317,000USD22,479,000USD14,865,000USD5,716,000USD
    Net Debt-24,180,000USD-39,261,000USD-138,787,000USD-236,633,000USD-256,600,000USD-62,691,000USD-10,607,000USD-3,929,000USD
    Short Term Debt3,186,000USD3,132,000USD3,221,000USD2,492,000USD1,567,000USD1,215,000USD——
    Short Long Term Debt Total14,738,000USD17,234,000USD20,924,000USD21,023,000USD20,944,000USD21,639,000USD114,083,000USD3,113,000USD
    Short Term Investments119,612,000USD119,808,000USD0USD—0USD10,284,000USD51,793,000USD100,986,000USD
    Net Receivables342,000USD——435,000USD214,000USD2,731,000USD935,000USD—
    Accounts Payable4,739,000USD4,830,000USD2,625,000USD4,404,000USD3,263,000USD1,552,000USD1,052,000USD538,000USD
    Property Plant Equipment Net28,481,000USD36,752,000USD44,201,000USD48,979,000USD35,001,000USD25,856,000USD2,121,000USD321,000USD
    Property Plant Equipment Gross55,868,000USD58,067,000USD59,048,000USD57,732,000USD41,327,000USD30,720,000USD——
    Accumulated Other Comprehensive Income102,000USD16,000USD0USD0USD-338,938,000USD24,000USD23,000USD-41,000USD
    Common Stock Shares Outstanding6,891,336shares5,491,652shares2,690,150shares2,567,518shares1,934,510shares457,499shares1,159,945shares1,862,392shares
    Non Current Assets Total31,429,000USD40,083,000USD45,023,000USD69,652,000USD56,500,000USD53,499,000USD17,401,000USD405,000USD
    Non Current Liabilities Total11,614,000USD14,218,000USD17,833,000USD18,645,000USD19,492,000USD21,529,000USD127,088,000USD19,000USD
    Non Current Liabilities Other62,000USD116,000USD130,000USD114,000USD115,000USD980,000USD——
    Non Currrent Assets Other76,000USD3,331,000USD822,000USD1,211,000USD2,037,000USD1,837,000USD4,692,000USD-1USD
    Net Working Capital139,395,000USD160,744,000USD142,985,000USD241,331,000USD266,121,000USD77,857,000USD——
    Unclassified Non Current Assets2,872,000USD————4,527,000USD——
    Unclassified Non Current Liabilities11,552,000USD14,102,000USD17,703,000USD18,531,000USD19,377,000USD20,549,000USD127,088,000USD—
    Unclassified Equity773,785,000USD684,471,000USD550,939,000USD530,444,000USD810,383,000USD216,124,000USD9,254,000USD175,635,000USD
    Good Will——0USD19,462,000USD19,462,000USD20,089,000USD——
    Other Assets——1USD————1USD
    Inventory———2,567,000USD4,678,000USD-3,094,000USD672,000USD—
    Current Deferred Revenue————4,805,000USD13,980,000USD10,993,000USD—
    Long Term Investments————0USD0USD10,588,000USD—
    Unclassified Current Assets————-4,678,000USD———
    Intangible Assets—————1,190,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-20,244,000USD-30,516,000USD-26,856,000USD-31,217,000USD-28,214,000USD-28,727,000USD-30,478,000USD-29,901,000USD
    Depreciation1,342,000USD1,469,000USD1,573,000USD1,655,000USD1,680,000USD1,623,000USD1,310,000USD1,602,000USD
    Stock Based Compensation1,303,000USD5,650,000USD2,529,000USD2,908,000USD3,180,000USD3,773,000USD6,777,000USD6,004,000USD
    Other Non Cash Items-47,000USD-152,000USD-23,000USD-37,000USD-348,000USD-564,000USD-4,514,000USD793,000USD
    Change In Working Capital-3,844,000USD2,640,000USD470,000USD58,000USD-1,695,000USD-206,000USD4,899,000USD-1,920,000USD
    Total Cash From Operating Activities-21,490,000USD-20,909,000USD-22,307,000USD-26,633,000USD-25,397,000USD-24,101,000USD-22,006,000USD-23,422,000USD
    Capital Expenditures-37,000USD-10,000USD-209,000USD-47,000USD-1,492,000USD-176,000USD-401,000USD-302,000USD
    Free Cash Flow-21,527,000USD-20,899,000USD-22,516,000USD-26,680,000USD-26,889,000USD-24,277,000USD-22,407,000USD-23,724,000USD
    Investments18,916,000USD-44,545,000USD16,836,000USD32,953,000USD-2,861,000USD-22,120,000USD-96,581,000USD-302,000USD
    Total Cashflows From Investing Activities18,879,000USD-44,535,000USD16,836,000USD32,953,000USD-2,861,000USD-22,120,000USD-96,581,000USD-302,000USD
    Total Cash From Financing Activities-65,000USD75,232,000USD-150,000USD267,000USD-104,000USD137,000USD-96,180USD204,000USD
    Change In Cash-2,673,000USD9,788,000USD-5,621,000USD6,587,000USD-28,362,000USD-46,084,000USD-118,587,000USD-23,520,000USD
    Begin Period Cash Flow38,918,000USD32,002,000USD37,623,000USD31,036,000USD59,398,000USD105,482,000USD224,069,000USD247,589,000USD
    End Period Cash Flow36,245,000USD41,790,000USD32,002,000USD37,623,000USD31,036,000USD59,398,000USD105,482,000USD224,069,000USD
    Other Cashflows From Investing Activities39,000,000USD2,000,000USD44,000,000USD66,000,000USD—11,000,000USD-96,180,000USD—
    Other Cashflows From Financing Activities-65,000USD75,232,000USD-150,000USD267,000USD-103,896USD14,875,000USD92,044,796USD204,000USD
    Unclassified Investing Cash Flow-39,000,000USD-1,980,000USD-43,791,000USD-65,953,000USD1,492,000USD-10,824,000USD96,581,000USD—
    Net Borrowings—0USD——————
    Sale Purchase Of Stock—-104USD104USD—-104USD—-96,180USD—
    Issuance Of Capital Stock—75,172,000USD0USD0USD0USD0USD0USD0USD
    Unclassified Financing Cash Flow—————-14,738,000USD-92,044,796USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-116,803,000USD-117,122,000USD-142,658,000USD-69,790,000USD-61,999,000USD-36,678,000USD-28,138,000USD-9,299,000USD
    Depreciation2,288,000USD6,468,000USD6,098,000USD2,575,000USD1,538,000USD1,226,000USD1,238,000USD1,222,000USD
    Stock Based Compensation14,267,000USD22,233,000USD20,259,000USD17,126,000USD12,511,000USD5,263,000USD1,175,000USD2,479,000USD
    Other Non Cash Items3,529,000USD1,568,000USD22,332,000USD2,580,000USD1,724,000USD-1,041,000USD-2,498,000USD-4,536,000USD
    Change In Working Capital1,473,000USD-5,525,000USD252,000USD2,744,000USD-6,057,000USD-13,524,000USD341,000USD-8,046,000USD
    Total Cash From Operating Activities-95,246,000USD-92,378,000USD-93,717,000USD-44,765,000USD-51,052,000USD-41,552,000USD-27,882,000USD-18,180,000USD
    Capital Expenditures-1,738,000USD-1,118,000USD-4,464,000USD-16,782,000USD-13,046,000USD-990,000USD-1,070,000USD-876,000USD
    Free Cash Flow-96,984,000USD-93,496,000USD-98,181,000USD-61,547,000USD-64,098,000USD-42,542,000USD-28,952,000USD-19,056,000USD
    Investments4,131,000USD-119,242,000USD-4,464,000USD-16,782,000USD-2,796,000USD115,217,000USD——
    Total Cashflows From Investing Activities2,393,000USD-119,242,000USD-4,464,000USD-16,782,000USD-2,796,000USD115,217,000USD-47,931,000USD-16,058,000USD
    Net Borrowings-150,000USD0USD——————
    Total Cash From Financing Activities75,245,000USD111,307,000USD236,000USD41,509,000USD242,685,000USD303,000USD76,945,000USD11,046,000USD
    Issuance Of Capital Stock75,172,000USD110,918,000USD0USD43,360,000USD238,129,000USD0USD——
    Change In Cash-17,608,000USD-100,313,000USD-97,945,000USD-20,038,000USD188,837,000USD73,968,000USD1,132,000USD-23,192,000USD
    Begin Period Cash Flow59,398,000USD159,711,000USD257,656,000USD277,694,000USD88,857,000USD14,889,000USD13,757,000USD36,949,000USD
    End Period Cash Flow41,790,000USD59,398,000USD159,711,000USD257,656,000USD277,694,000USD88,857,000USD14,889,000USD13,757,000USD
    Other Cashflows From Investing Activities145,000,000USD11,000,000USD——10,250,000USD64,114,000USD-46,861,000USD-7,500,000USD
    Other Cashflows From Financing Activities-104,000USD389,000USD-150,000USD-1,851,000USD4,556,000USD-157,000USD76,945,000USD11,046,000USD
    Unclassified Investing Cash Flow-145,000,000USD-9,882,000USD4,464,000USD16,782,000USD2,796,000USD-63,124,000USD—-7,682,000USD
    Sale Purchase Of Stock——-150,000USD-3,234,000USD————
    Change To Account Receivables———185,000USD-30,000USD0USD——
    Unclassified Financing Cash Flow———46,594,000USD————
    Change To Inventory————2,011,000USD———
    Unclassified Operating Cash Flow————1,231,000USD3,202,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q4 2018Quarterly · 2018-12-31ProductActive Pharmaceutical Ingredients29,510,000USD0001144204-19-008980
    Q4 2018Quarterly · 2018-12-31ProductAgricultural Protection Products5,044,000USD0001144204-19-008980
    Q4 2018Quarterly · 2018-12-31ProductFinished Dosage Form Generic Drugs73,663,000USD0001144204-19-008980
    Q4 2018Quarterly · 2018-12-31ProductNutraceutical Products11,318,000USD0001144204-19-008980
    Q4 2018Quarterly · 2018-12-31ProductPharmaceutical Intermediates12,532,000USD0001144204-19-008980
    Q4 2018Quarterly · 2018-12-31ProductSpecialty Chemicals31,582,000USD0001144204-19-008980
    Q4 2018Quarterly · 2018-12-31SegmentHuman Health84,981,000USD0001144204-19-008980
    Q4 2018Quarterly · 2018-12-31SegmentPerformance Chemicals36,626,000USD0001144204-19-008980
    Q4 2018Quarterly · 2018-12-31SegmentPharmaceutical Ingredients42,042,000USD0001144204-19-008980
    Q3 2018Quarterly · 2018-09-30ProductActive Pharmaceutical Ingredients28,626,000USD0001144204-18-058572
    Q3 2018Quarterly · 2018-09-30ProductAgricultural Protection Products8,490,000USD0001144204-18-058572
    Q3 2018Quarterly · 2018-09-30ProductFinished Dosage Form Generic Drugs69,213,000USD0001144204-18-058572
    Q3 2018Quarterly · 2018-09-30ProductNutraceutical Products11,633,000USD0001144204-18-058572
    Q3 2018Quarterly · 2018-09-30ProductPharmaceutical Intermediates10,222,000USD0001144204-18-058572
    Q3 2018Quarterly · 2018-09-30ProductSpecialty Chemicals36,221,000USD0001144204-18-058572
    Q3 2018Quarterly · 2018-09-30SegmentHuman Health80,846,000USD0001144204-18-058572
    Q3 2018Quarterly · 2018-09-30SegmentPerformance Chemicals44,711,000USD0001144204-18-058572
    Q3 2018Quarterly · 2018-09-30SegmentPharmaceutical Ingredients38,848,000USD0001144204-18-058572
    FY 2018Yearly · 2018-06-30GeographyAsia Pacific30,329,000USD0001144204-18-051414
    FY 2018Yearly · 2018-06-30GeographyFrance36,644,000USD0001144204-18-051414
    FY 2018Yearly · 2018-06-30GeographyGermany96,708,000USD0001144204-18-051414
    FY 2018Yearly · 2018-06-30GeographyNetherlands11,980,000USD0001144204-18-051414
    FY 2018Yearly · 2018-06-30GeographyUnited States535,698,000USD0001144204-18-051414
    FY 2018Yearly · 2018-06-30SegmentHuman Health374,514,000USD0001144204-18-051414
    FY 2018Yearly · 2018-06-30SegmentPerformance Chemicals177,991,000USD0001144204-18-051414
    FY 2018Yearly · 2018-06-30SegmentPharmaceutical Ingredients158,854,000USD0001144204-18-051414
    Q1 2018Quarterly · 2018-03-31SegmentHuman Health91,926,000USD0001144204-18-025570
    Q1 2018Quarterly · 2018-03-31SegmentPerformance Chemicals50,871,000USD0001144204-18-025570
    Q1 2018Quarterly · 2018-03-31SegmentPharmaceutical Ingredients43,201,000USD0001144204-18-025570
    Q4 2017Quarterly · 2017-12-31ProductActive Pharmaceutical Ingredients23,790,000USD0001144204-19-008980
    Q4 2017Quarterly · 2017-12-31ProductAgricultural Protection Products3,601,000USD0001144204-19-008980
    Q4 2017Quarterly · 2017-12-31ProductFinished Dosage Form Generic Drugs90,761,000USD0001144204-19-008980
    Q4 2017Quarterly · 2017-12-31ProductNutraceutical Products12,705,000USD0001144204-19-008980
    Q4 2017Quarterly · 2017-12-31ProductPharmaceutical Intermediates9,839,000USD0001144204-19-008980
    Q4 2017Quarterly · 2017-12-31ProductSpecialty Chemicals30,533,000USD0001144204-19-008980
    Q4 2017Quarterly · 2017-12-31SegmentHuman Health103,466,000USD0001144204-19-008980
    Q4 2017Quarterly · 2017-12-31SegmentPerformance Chemicals34,134,000USD0001144204-19-008980
    Q4 2017Quarterly · 2017-12-31SegmentPharmaceutical Ingredients33,629,000USD0001144204-19-008980
    Q3 2017Quarterly · 2017-09-30ProductActive Pharmaceutical Ingredients26,440,000USD0001144204-18-058572
    Q3 2017Quarterly · 2017-09-30ProductAgricultural Protection Products8,644,000USD0001144204-18-058572
    Q3 2017Quarterly · 2017-09-30ProductFinished Dosage Form Generic Drugs95,561,000USD0001144204-18-058572
    Q3 2017Quarterly · 2017-09-30ProductNutraceutical Products10,454,000USD0001144204-18-058572
    Q3 2017Quarterly · 2017-09-30ProductPharmaceutical Intermediates10,136,000USD0001144204-18-058572
    Q3 2017Quarterly · 2017-09-30ProductSpecialty Chemicals34,020,000USD0001144204-18-058572
    Q3 2017Quarterly · 2017-09-30SegmentHuman Health106,015,000USD0001144204-18-058572
    Q3 2017Quarterly · 2017-09-30SegmentPerformance Chemicals42,664,000USD0001144204-18-058572
    Q3 2017Quarterly · 2017-09-30SegmentPharmaceutical Ingredients36,576,000USD0001144204-18-058572
    FY 2017Yearly · 2017-06-30GeographyAsia Pacific29,790,000USD0001144204-18-051414
    FY 2017Yearly · 2017-06-30GeographyFrance35,796,000USD0001144204-18-051414
    FY 2017Yearly · 2017-06-30GeographyGermany79,105,000USD0001144204-18-051414
    FY 2017Yearly · 2017-06-30GeographyNetherlands9,949,000USD0001144204-18-051414
    FY 2017Yearly · 2017-06-30GeographyUnited States483,678,000USD0001144204-18-051414
    FY 2017Yearly · 2017-06-30SegmentHuman Health315,395,000USD0001144204-18-051414
    FY 2017Yearly · 2017-06-30SegmentPerformance Chemicals165,478,000USD0001144204-18-051414
    FY 2017Yearly · 2017-06-30SegmentPharmaceutical Ingredients157,445,000USD0001144204-18-051414
    Q1 2017Quarterly · 2017-03-31SegmentHuman Health99,816,000USD0001144204-18-025570
    Q1 2017Quarterly · 2017-03-31SegmentPerformance Chemicals46,491,000USD0001144204-18-025570
    Q1 2017Quarterly · 2017-03-31SegmentPharmaceutical Ingredients43,821,000USD0001144204-18-025570
    Q4 2016Quarterly · 2016-12-31SegmentHuman Health53,981,000USD0001144204-18-005329
    Q4 2016Quarterly · 2016-12-31SegmentPerformance Chemicals34,755,000USD0001144204-18-005329
    Q4 2016Quarterly · 2016-12-31SegmentPharmaceutical Ingredients36,816,000USD0001144204-18-005329
    Q3 2016Quarterly · 2016-09-30SegmentHuman Health47,889,000USD0001144204-17-056166
    Q3 2016Quarterly · 2016-09-30SegmentPerformance Chemicals39,513,000USD0001144204-17-056166
    Q3 2016Quarterly · 2016-09-30SegmentPharmaceutical Ingredients40,616,000USD0001144204-17-056166
    FY 2016Yearly · 2016-06-30GeographyAsia Pacific34,581,000USD0001144204-18-051414
    FY 2016Yearly · 2016-06-30GeographyFrance30,177,000USD0001144204-18-051414
    FY 2016Yearly · 2016-06-30GeographyGermany76,666,000USD0001144204-18-051414
    FY 2016Yearly · 2016-06-30GeographyNetherlands16,217,000USD0001144204-18-051414
    FY 2016Yearly · 2016-06-30GeographyUnited States400,883,000USD0001144204-18-051414
    FY 2016Yearly · 2016-06-30SegmentHuman Health228,035,000USD0001144204-18-051414
    FY 2016Yearly · 2016-06-30SegmentPerformance Chemicals169,478,000USD0001144204-18-051414
    FY 2016Yearly · 2016-06-30SegmentPharmaceutical Ingredients161,011,000USD0001144204-18-051414
    FY 2015Yearly · 2015-06-30GeographyAsia Pacific27,329,000USD0001144204-17-045100
    FY 2015Yearly · 2015-06-30GeographyFrance27,976,000USD0001144204-17-045100
    FY 2015Yearly · 2015-06-30GeographyGermany69,889,000USD0001144204-17-045100
    FY 2015Yearly · 2015-06-30GeographyNetherlands14,656,000USD0001144204-17-045100
    FY 2015Yearly · 2015-06-30GeographyUnited States407,101,000USD0001144204-17-045100
    FY 2015Yearly · 2015-06-30SegmentHuman Health225,263,000USD0001144204-17-045100
    FY 2015Yearly · 2015-06-30SegmentPerformance Chemicals172,392,000USD0001144204-17-045100
    FY 2015Yearly · 2015-06-30SegmentPharmaceutical Ingredients149,296,000USD0001144204-17-045100
    FY 2014Yearly · 2014-06-30GeographyAsia Pacific26,159,000USD0001571049-16-017785
    FY 2014Yearly · 2014-06-30GeographyFrance29,412,000USD0001571049-16-017785
    FY 2014Yearly · 2014-06-30GeographyGermany84,024,000USD0001571049-16-017785
    FY 2014Yearly · 2014-06-30GeographyNetherlands14,869,000USD0001571049-16-017785
    FY 2014Yearly · 2014-06-30GeographyUnited States355,715,000USD0001571049-16-017785
    FY 2014Yearly · 2014-06-30SegmentHuman Health160,217,000USD0001571049-16-017785
    FY 2014Yearly · 2014-06-30SegmentPerformance Chemicals173,537,000USD0001571049-16-017785
    FY 2014Yearly · 2014-06-30SegmentPharmaceutical Ingredients176,425,000USD0001571049-16-017785
    FY 2013Yearly · 2013-06-30GeographyAsia Pacific28,402,000USD0001571049-15-007509
    FY 2013Yearly · 2013-06-30GeographyFrance38,475,000USD0001571049-15-007509
    FY 2013Yearly · 2013-06-30GeographyGermany92,053,000USD0001571049-15-007509
    FY 2013Yearly · 2013-06-30GeographyNetherlands14,513,000USD0001571049-15-007509
    FY 2013Yearly · 2013-06-30GeographyUnited States326,247,000USD0001571049-15-007509
    FY 2013Yearly · 2013-06-30SegmentHuman Health129,667,000USD0001571049-15-007509
    FY 2013Yearly · 2013-06-30SegmentPerformance Chemicals185,171,000USD0001571049-15-007509
    FY 2013Yearly · 2013-06-30SegmentPharmaceutical Ingredients184,852,000USD0001571049-15-007509
    FY 2012Yearly · 2012-06-30GeographyAsia Pacific25,277,000USD0001571049-14-004448
    FY 2012Yearly · 2012-06-30GeographyFrance33,143,000USD0001571049-14-004448
    FY 2012Yearly · 2012-06-30GeographyGermany82,600,000USD0001571049-14-004448
    FY 2012Yearly · 2012-06-30GeographyNetherlands13,738,000USD0001571049-14-004448

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.